The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.
